2025+ISUOG共识声明：妊娠期高血压疾病和胎儿生长受限的母体血流动力学评估

INTRODUCTION

Pregnancy presents a unique cardiovascular challenge.Profound maternal hemodynamic adjustments result from a complex interplay between the maternal cardiovascular system and uteroplacental perfusion, which permits fetal development while maintaining healthy maternal homeostasis1-5. Failure to meet this challenge can lead to maternal hypertensive complications(hypertensive disorders of pregnancy(HDP)) and/or fetal growth disorders(fetal growth restriction(FGR))^{6-9}.

Monitoring and management of HDP and FGR has been based largely on maternal blood pressure(BP)monitoring and fetal growth assessment ${}^{10}$ . Promising research offers the prospect of a less reactive and more

proactive approach. Maladaptation to the requirements of pregnancy can be detected in a preclinical phase of HDP and FGR by maternal hemodynamic assessment,offering opportunities for targeted hemodynamic inter-ventions11-15. Pregnancy also serves as a stress test for future cardiovascular health, especially if superimposed upon subclinical cardiometabolic or cardiovascular vul-nerabilities11,16-19.

This Consensus Statement provides an update on the role of maternal hemodynamic assessment in HDP and FGR.

METHODS

A proposal for this Consensus Statement was submitted to and evaluated by the ISUOG CSC. The authors of this Consensus are members of the International Working Group on Maternal Hemodynamics(https://maternal hemodynamics.com/) and were involved in both the development and the writing stages. Members of the International Working Group on Maternal Hemody-namics who were not involved in the writing of this Consensus were invited to review the document (review-ing group) and those who responded are acknowledged.Kashholders were not included in the writing process.

This process was not intended to represent a systematic review. The preselected topics were divided among the authors, who worked in pairs and performed a literature search. T.S. collated the document and proposed the key points. The final document and key points were revised by all authors. Several meetings were organized to discuss any points on which there was not initial consensus, until complete agreement was reached. The document was then finalized after comments from the reviewing group, the ISUOG CSC and the ISUOG Board of Trustees.

The authors of this Consensus Statement are experts in the field of maternal hemodynamics and have expressed their opinion based on the available literature and evidence. Any clinician applying this Consensus is expected to use their independent medical judgement in the context of the individual clinical circumstances to determine patient care.

2

Consensus Statement

# MATERNAL HEMODYNAMIC ASSESSMENT: METHODOLOGY AND REPRODUCIBILITY

Traditionally, peripheral BP is measured by auscultation using an arm cuff connected to a manometer. Increasingly,automated oscillometric devices, validated for pregnancy,are becoming the recommended standard20,21. Further developments have allowed additional analysis of the arterial waveform for estimation of central BP and arterial function. Markets of arterial stiffness and compliance,such as pulsed-wave velocity and the augmentation index(AIx)22,23, help to understand the pathophysiology behind HDP and FGR, predict cardiovascular complications,and evaluate and direct prevention and treatment24-26.

Cardiac output

Assessment of central hemodynamic factors that deter-mine BP(cardiac output(CO, in L/min) and systemic vascular resistance(SVR, in dyne.s/cm5)) is increasingly accessible using easily operable devices27. Considering the pivotal role of central hemodynamic functioning, this Consensus Statement focuses primarily on CO assessment.

CO is the product of stroke volume(SV) and heart rate(HR)(CO=SVxHR). Accuracy of its evaluation is improved by averaging measurements over several heartbeats3-5, to compensate for respiratory variations.After 20 gestational weeks, CO is best evaluated with the woman in a left lateral positest, to minimize caval and aortic compression by the gravid uterus-28,22.The heart can rapidly modulate CO in order to meet the demands of pregnancy, with a wide range of normality(4-20 L/min) depending on activity level,age, fitness, body size, gestational age and metabolic rate. While trimester-specific reference ranges exist,device-specific normalization, that takes into account maternal age and posture, does not. Indexing for actual or prepregnancy body surface area or height may be of additional value when comparing measurements between individuals27,30-32. Individual or separate CO measurements can be of value for instant hemodynamic assessment, while repeated or continuous measurements are appropriate for trend analysis.

With knowledge of CO and BP, SVR can be calculated((SVR=80x(MAP-RAP)/CO) in dyne.s/cm5), where MAP represents mean arterial pressure and RAP is right atrial pressure,RAP(or central venous pressure) is usually low in pregnancy(0-5mmHg) and therefore is usually omitted from the calculation ${}^{33,34}$ . Aterrial function can also be evaluated by Doppler assessment of peripheral vessels, for example the uterine and/or ophthalmic arteries.

Reference techniques

CO is determined most accurately by invasive measure-ments using thermodilution or indicator(lithium) dilu-tion, or by cardiac magnetic resonance imaging(MRI).The former require insertion of intracardiac, central

venous and/or arterial catheters(e.g. pulmonary artery catheters), limiting their indication to critically ill preg-nant women in an intensive care unit setting ${}^{33,34}$ . Cardiac MRI is non-invasive, but its limited availability and high cost restrict its use in an obstetric context28,35

Ultrasound

Transthoracic echocardiography permits non-invasive assessment of CO by measuring the left ventricular outflow tract diameter and pulsed-wave Doppler outflow signal along with HR. It has been validated against inva-sive measurements in severely ill pregnant women and can be considered an alternative reference technique36,37 Transthoracic echocardiography enables evaluation of systolic and/or diastolic function(assessing ejection fraction using two-dimensional and/or M-mode imaging,strain and strain rate using speckle tracking, tricuspid annular plane systolic excursion(TAPSE), and mitral inflow using pulse-wave and tissue Doppler imaging) and preload assessment(atrial size and inferior vena cava size and collapsibility)38-40.

Other techniques

Another means of assessing CO is with a non-invasive mobile device, using a continuous-wave Doppler trans-ducer placed in the suprasternal notch40. This technique is limited by assumptions regarding the left ventricular outflow tract diameter and acoustic guidance for probe orientation. However, by including more heartbeats in the calculation, the accuracy is enhanced.

An inert gas rebreathing technique can be used to calculate CO based on Fickir's principle41. A blood-soluble and an insoluble gas are delivered though a closed breathing assembly and relative levels over a few respiratory cycles are measured by a gas analyzer in the mouthpiece. As with pulmonary artery catheters,pulmonary blood flow or right ventricular output is measured, which is usually identical to left ventricular output. In obstetrics, this technique is more suited for research than clinical practice ${}^{42}$ .

With impedance and reactance cardiography, a very-low-amplitude high-frequency current is transmit-ted between skin electrodes on the thorax. CO can be estimated by calculating differences in impedance(bioimpedance) or phase shifts(bioreactance) induced by changing blood flow during the cardiac cycle43,44 Pulse-contour analysis estimates CO from a peripheral arterial waveform, which can be obtained invasively or non-invasively ${}^{33,45}$ . Both impedance and reac-tance cardiography and pulse-contour methods are operator-independent and permit continuous monitoring for trend analysis, but their algorithms to calculate CO are based on assumptions that may affect accuracy.

Most non-invasive techniques lack validation in pregnancy against reference techniques. The few that have been compared with reference techniques often fail the current rigorous standards for absolute values and trend

Consensus Statement

3

analysis ${ }^{46}$ . Consequently, CO values obtained with one technique are not comparable with those obtained using another technique, and the techniques cannot be used interchangeably. Still, it would be unwise to disregard the benefits from these devices, as their accessibility permits the gathering of large amounts of valuable hemodynamic information. In addition, using a single device repeatedly in the same patient overcomes the differences between techniques and allows the investigation of changes over time. As such, these techniques may be valuable for monitoring changes as pregnancy progresses.

Key points

● After 20 gestational weeks, the assessment of maternal CO should be performed with the woman in a left lateral position.

● While no non-invasive technique is a true gold standard for CO assessment in pregnancy, transthoracic echocardiography has undergone extensive validation.

● Different techniques for non-invasive assessment of maternal CO cannot be used interchangeably.

● Despite the lack of rigorous standardization and systematic differences between techniques, evaluation of the changes in maternal CO over time might be valuable in obstetric practice.

MATERNAL HEMODYNAMIC ADAPTATION TO HEALTHY PREGNANCY

During pregnancy, the mother's body undergoes cardio-vascular changes leading to hemodynamic adaptations required to respond to the increasing metabolic and oxy-gen demands from the uterus, placenta and fetus and to prepare the mother for possible blood loss during delivery(Figure 1). To understand the possible role of maternal hemodynamics in pathological conditions, it is important to understand these changes in healthy pregnancy, as nor-mal maternal hemodynamic adaptation is a prerequisite for development of a normal pregnancy 42,47.

Maternal hemodynamic changes in healthy pregnancy

Maternal hemodynamic changes can be observed during the menstrual cycle. Compared to the follicular phase,during the luteal phase, the HR, plasma volume(PV),CO and central and peripheral arterial compliance are increased, while the MAP and SVR are decreased48.Similar changes are present early in pregnancy, from 6 weeks of gestation, prior to the development of a placental circulation 42,48,49.

The hypothesized mechanism underlying maternal hemodynamic changes in early pregnancy(Figure 2)is that a fall in SVR, by up to 20-25%50, acts as the trigger event, most likely due to reduced vascular

 Figure 1 Major maternal hemodynamic changes in healthy pregnancy. CO, cardiac output; GFR, glomerular filtration rate; HR, heart rate;IVRT, isovolumetric relaxation time; LA, left atrial; LV, left ventricular; MAP, mean arterial pressure; RAAS, renin-angiotensin-aldosterone system; RBC, red blood cells; SV, stroke volume; SVR, systemic vascular resistance.

4

Consensus Statement

 Figure 2 Early maternal hemodynamic changes in healthy pregnancy. hCG, human chorionic gonadotropin; NO, nitric oxide, Pg, pro-gesterone; RAAS, renin-angiotensin-aldosterone system.

tone, leading to a decrease in MAP and a compen-satory increase in CO51. The initial increase in CO is caused by an increase in HR48. These changes are accompanied by renin-angiotensin-aldosterone-system(RAAS) activation due to increases in renal plasma flow and glomerular filtration rate and reduction in MAP48,51. The result of RAAS activation is sodium and water reabsorption, with consequent PV expansion,hemodilution and increased preload52. The increased preload leads to improved cardiac filling during diastole.Together with decreased cardiac afterload, this results in increased SV and, consequently, in increased CO48.As a result of increased preload, the maternal heart undergoes changes: the left atrial diameter, left ventricular diastolic and systolic dimensions and ventricular wall thickness all increase, resulting overall in increased cardiac mass, surface area(so-called myocardial eccentric hypertrophy) and performance5,53. Maternal cardiac morphological changes start at around 8 weeks of gestation52.

The maintenance of CO is also guaranteed by decreased cardiac afterload, which is accomplished by the decrease in SVR, while the normal perfusion pressure is associ-ated with higher arterial compliance ${}^{54}$ . Concomitantly,increased venous compliance accommodates a higher quantity of PV, contributing to preload increase and further maintenance of CO48.

A detailed discussion of molecular pathways is beyond the scope of this document, but it has been hypothesized that hormonal influences, including estro-gen and human chorionic gonadotropin secreted by the syncirotrophoblast, and other factors(e.g. relaxin,

vascular endothelial factor, nitric oxide(NO)) play a role in physiological maternal hemodynamic adaptation early in pregnancy ${}^{48}$ , which would mean that the earliest maternal hemodynamic changes in pregnancy develop independently from the fetoplacental unit.

After the early first-trimester changes, healthy preg-nancy is characterized by various hemodynamic adapta-tions, including further increases in CO and PV, decreases in SVR and MAP, and changes in maternal cardiac function.

Cardiac output

Increasing cardiac preload and concomitant decreasing afterload result in progressively higher SV and CO in the first trimester of pregnancy. SV increases by 15-25% early in pregnancy and plateaus by about 20 weeks 55,56. In the second half of pregnancy, the increase in SV is reversed, so that near term there is no difference between pregnant and non-pregnant women ${}^{56}$ .The increased CO is also caused by the higher maternal HR, which increases by 15-30% early in pregnancy and continues to increase gradually until term. The CO increases overall by 20-50% and peaks by mid to late pregnancy, reaching a maximum mean difference of 1.41 L/min between 29 and 35 weeks of gestation 55,56. It remains controversial as to whether CO increases until term ${}^{57}$ or decreases late in pregnancy ${}^{58}$ ; inconsistencies in results between studies can be explained by differences in their design and/or methodology, population and other factors. CO returns to prepregnancy values from 2 weeks postpartum ${}^{1}$ .

Consensus Statement

5

Plasma volume

PV starts to increase early in pregnancy, peaks during the second trimester and changes minimally throughout the third trimester, returning to normal levels after 6 weeks postpartum4. Around one-third of the PV is contained in the arterial compartment, while two-thirds are located in the venous compartment and represent a hemodynamically inactive intravascular volume59.

Systemic vascular resistance

SVR decreases, with an overall 30% decrease early in pregnancy55 and nadir in the late second trimester56.

Mean arterial pressure

MAP decreases during pregnancy until 24 weeks of gestation, because the increase in CO is not sufficient to balance the fall in SVR. Both systolic and diastolic BP decrease; however, the reduction in diastolic BP is greater than that in central and brachial systolic BP49. There is also a significant fall in AIX(i.e. arterial stiffness), which explains the reduced central systolic BP. Central systolic BP reflects better than brachial systolic BP the uterine artery pressure, which contributes to the uteroplacental perfusion49. The BP returns to baseline levels during the third trimester55,56.

Maternal heart

Increased preload and concomitant decreased afterload have a positive effect on maternal cardiac function in the first trimester of pregnancy. The change in left ventricular diastolic function in the first trimester appears to be determined by an increased contribution of passive left ventricular filling4. In advanced gestation, left ventricular diastolic function seems to worsen progressively, as reflected by a decreased E-wave to A-wave(E/A) ratio4.

Morphological changes start in the first trimester and continue throughout pregnancy, peaking around 30 weeks. The left ventricular mass increases by approximately 50%55. Myocardial eccentric hypertrophy observed during healthy pregnancy represents a reversible and uncomplicated phenomenon that has usually resolved by 6 months postpartum60,61.

Key points

● Important maternal hemodynamic changes occur in the first weeks of pregnancy.

● Placentation is not necessary for maternal hemody-namic changes to occur in early healthy pregnancy.

•Maternal hemodynamic changes are important for adequate uterine and placental perfusion and adequate nutrient and oxygen supply to the placenta and fetus.

● Maternal hemodynamic changes represent a reversible process in healthy pregnancy, which reverts in the postpartum period.

- It is crucial to understand the physiological maternal hemodynamic changes that take place in healthy pregnancy, in order to understand their role in pathological conditions.

MATERNAL HEMODYNAMIC ADAPTATION TO MULTIPLE PREGNANCY

More profound maternal hemodynamic changes have been reported in uncomplicated multiple compared with singleton pregnancies, including higher CO and lower SVR across gestation62-64. The greater increase of circulating blood volume and the higher concentrations of vasodilating hormones, such as prostaglandins and progesterone, are thought to drive these changes65.

In uncomplicated twin gestation, changes in maternal systolic and diastolic function have been documented from the first to the third trimester66-68. In particular,diastolic and mean BP show a U-shaped trend through gestation, reaching their nadir at midgestation. Based on serial echocardiograms, left ventricular systolic function,expressed either by classical parameters(ejection fraction or fractional shortening) or by tissue Doppler parameters(longitudinal contractility, quantified by S'(myocardial velocity during isovolumetric longitudinal contraction))worsens progressively during pregnancy 62,67. Moreover,relative diastolic dysfunction is observed, as evidenced by a progressive reduction in the mitral E-wave and an increase in the A-wave velocities, together with consistent modifications of the tissue Doppler parameters(reduction in E' and increase in A')67. These findings indicate that the maternal heart is subjected to profound adjustments during the course of a twin gestation, regardless of whether there are cardiovascular complications.

The progressive decrease of ventricular performance may depend on the volume overload65, and, in the late stages of apparently uneventful twin gestation,may lead to increased end-systolic residual volumes in the ventricle, thus contrasting with the early diastolic phase and promoting active atrial contribution to left ventricular filling across the atrioventricular valves. In other words, the late stages of an uncomplicated twin pregnancy at the level of the maternal heart may mimic diastolic dysfunction as observed in the early stages of chronic cardiac insufficiency. It is noteworthy that similar findings, suggestive of early diastolic dysfunction,have been described at postpartum echocardiography in women who developed preterm or severe pre-eclampsia(PE) in a singleton gestation, ${}^{17,69}$

At second-trimestar maternal echocardiography, the left ventricular mass is increased in twin pregnancies compared with singletons, but there are only subtle differences in systolic and diastolic left ventricular functional indices70. The pattern of cardiac changes is similar between monochorionic and dichorionic twin pregnancies. These cardiovascular changes resemble those seen in singletons in late gestation and suggest physiological remodeling in response to the increase

6

Consensus Statement

in volume loading rather than decompensation of the maternal cardiovascular system.

Changes in maternal cardiac function in uncomplicated twin gestation, from early to late pregnancy, include an increase in CO and a parallel decrease in SVR. It is unclear how these cardiac findings differ with respect to chorionicity. Using serial transthoracic echocardiography,one study reported lower maternal CO in second-trimester monochorionic vs dichorionic twin pregnancies, possibly because of the smaller increase in the circulating blood volume66. In contrast, another study recently showed a higher CO in the second trimester in monochorionic compared to dichorionic twin pregnancies68. Most cardiac parameters revert towards the values of early pregnancy soon after delivery, with the exception of some indices of systolic function, such as fractional shortening, ejection fraction and tissue Doppler S', which have been reported to remain significantly below those observed in the first trimester67. This may indicate that the workload caused to the maternal heart by the increased circulating volumes may still affect the ventricular contractility in the early postpartum period and that complete recovery is delayed.

Key points

● Uncomplicated twin pregnancy is associated with more profound maternal hemodynamic changes than those seen in singleton pregnancy, and the maternal heart is exposed to more profound adjustments, most likely due to volume overload.

● Maternal left ventricular systolic function shows progressive worsening during uncomplicated twin pregnancy,

● In the late stages of uncomplicated twin pregnancy,there may be signs of maternal diastolic dysfunction.

MATERNAL HEMODYNAMICS IN HYPER-TENSIVE DISORDERS OF PREGNANCY

Maternal hemodynamics in pre-celampsia phenotypes

The first classification of PE phenotypes was based on the timing of clinical disease onset, before('early-onset') or after('late-onset') 34 weeks of gestation71,72. Early-onset PE typically follows a more aggressive course, present-ing with severe symptoms of maternal organ dysfunction or with poor fetal growth that precedes the develop-ment of maternal hypertension, in association with serum markers of immune and endothelium activation73. The maternal hemodynamic characteristics are markedly dif-ferent between the two phenotypes, both in the clinical14 and in the latent14,74 phase of the disease15. A new classifi-cation system has been proposed that is based on maternal hemodynamics and fetal growth14,15,75,76. PE associated with FGR is characterized by low CO and high SVR,in both preclinical and overt phases of the disease. PE associated with normal fetal growth is not characterized by low CO, while the SVR in the preclinical phase of the

disease is low and may increase in the overt phase. This classification allows discrimination between two PE phe-notypes, one characterized by vascular-resistance-induced hypertension('resistance-dominant HDP') and the other by intravascular-volume-induced hypertension('volume-dominant HDP')(Figure 3). As such, the fun-damental physiological definition of BP as the product of CO and SVR(Ohm's law) is pertinent: hypertension is the result of either increased SVR, increased CO or both ${}^{6,77}$ .

The theory that the placenta is the main etiological driver of PE is challenged by the observation of subclinical abnormal hemodynamic function already present in the preconception stage in women who subsequently developed PE4,78. An increasing number of clinical,epidemiological and experimental observations support that the abnormal placement process associated with PE is a result of, rather than a cause of, abnormal maternal hemodynamic function7. Latent suboptimal hemodynamic function before conception predisposes not only to gestational complications, but also to early-onset cardiovascular disease in later life ${}^{79-81}$ .Moreover, abnormal intrauterine hemodynamics may be a direct link between poor fetal growth and early-onset adult cardiovascular and renal disease82. While impaired maternal cardiovascular performance plays a role in the poor development of placenta, we should not overlook the contribution of immune-system dysfunction,which is observed when defective trophoblast invasion occurs in early gestation83. The association between confirmed poor maternal hemodynamics and the immune system should be a focus of future research ${}^{84}$ .

The classification of PE into resistance-dominant or volume-dominant phenotype challenges the reported lon-gitudinal hemodynamic evolution from early pregnancy until term in women who eventually develop PE6. In all studies reported since 1990, a hemodynamic imbalance between CO and SVR was present at all stages of preg-nancy in women who developed PE8,78,85. Early-onset PE typically presents with first-trimester increased SVR and a blunted rise of CO8. Late-onset PE, on the other hand,starts with high CO and normal SVR8. This imbalance can remain unchanged8,76, or convert from a high-CO circulation to a high-resistance circulation with advanc-ing gestation8, probably due to endothelial damage and intravascular overload86, thereby establishing a‘vicious circle' that, in association with hypoalbuminemia and impaired cerebral blood flow autoregulation, strongly predisposes to eclampsia87.

Gestational hypertension

Gestational hypertension(GH) also presents with both volume-dominant and resistance-dominant pheno-types ${}^{8,85}$ . Contrary to HDP associated with renal damage,abnormal maternal nervous Doppler characteristics are absent in GH6, raising the question as to whether PE-related symptoms of organ dysfunction may relate to venous congestion induced by increased intravenous

Consensus Statement

7

 Figure 3 Diagram representing two phenotypes of hypertensive disorders of pregnancy(HDP):(a) resistance-dominant HDP and(b)volume-dominant HDP. FGR, fetal growth restriction; AGA, appropriate-for-gestational age.

pressure, reduced venous capacitance or external venous compression due to raised intra-abdominal pressure ${}^{88}$ .

Overall, this evidence supports the abandonment of two traditional concepts of obstetrics. Firstly, the mechanistic time-dependent classification into early-onset and late-onset PE has no clinical relevance, and is meaningful only from an epidemiological perspective.Secondly, the very term‘pre-eclampsia’ no longer bears any clinical meaning once we recognize the truly different pathophysiological pathways, which simply share similar downstream symptoms. Thus, PE and GH should be considered under the same umbrella, that is, HDP, with different clinical facets. Accordingly, herein, we use the broader term,‘HDP’, unless otherwise indicated(e.g.when discussing studies focused only on PE).

Key points

● Maternal hemodynamic assessment differentiates two HDP phenotypes: resistance-dominant and volume-dominant(CO-dominant).

● These phenotypes are linked though not invariably to the gestational age at onset of HDP.

● The most important clinical factor that discriminates between the two HDP phenotypes is the presence of FGR.

● Abnormal maternal hemodynamic function is present in preconception and preclinical stages of HDP.

MATERNAL HEMODYNAMICS IN FETAL GROWTH RESTRICTION

Throughout healthy pregnancy, maternal CO correlates positively with fetal growth velocity and birth weight,and the physiological reduction in SVR is associated with increased birth weight. This is in line with the observation of an interaction between maternal cardiac and placental function 89; the decrease in SVR coincides with the reduction of resistance in the uteroplacental circulation.Moreover, there is a significant correlation between fetal Doppler indices and maternal hemodynamics. Maternal SVR,CO,heart contractility and dynamicity of circulation all seem to influence the blood flow rate in the umbilical vein 90. The evidence of a correlation between maternal, placental and fetal circulations 91 highlights the importance of hemodynamic assessment in cases of inadequate fetal growth.

The most common cause of FGR is so-called uteroplacental insufficiency, resulting from defective placentation, and, traditionally, FGR has been defined as a‘placental syndrome’92,93. The poorly functioning placenta restricts nutrient supply to the fetus and prevents

8

Consensus Statement

normal fetal growth. This condition is characterized by defective trophoblast invasion, abnormal uterine artery adaptation and increased placental vascular resistance.

A new interpretation of the pathophysiology of FGR has stemmed from the premise that placental function is dependent on its perfusion15,93. Thus, adequate systemic cardiovascular adaptation in pregnancy is crucial to ensure optimal placental function. Large population studies have identified the occurrence of FGR as an important risk factor for the development of cardiovascular disease later in a woman's life, with the highest risk in cases of the most severe and early FGR94,95,regardless of the simultaneous presence of PE.

The definition of FGR is based on fetal biometry and Doppler evaluation, and it is classified as early or late according to whether it presents before or after 32 weeks of pregnancy, respectively96.

Early fetal growth restriction

Early FGR has low incidence(0.5%) and is characterized by high-impedance uterine circulation, frequent associ-ation with HDP, high risk of perinatal mortality and morbidity, and poor neonatal outcome due to prematu-rity97. While it is known that defective trophoblast inva-sion with subsequent failure of spiral artery adaptation is associated with early FGR92, maternal hemodynamic assessment provides further insight, linking evidence of uteroplacental dysfunction with signs of maternal cardio-vascular impairment in pregnancies with early FGR.

Women with a prepregnancy or early-pregnancy abnormal maternal hemodynamic profile, with low CO,high SVR and a hypovolemic state, have an increased risk of developing FGR47,98, and this hemodynamic profile is maintained during the pregnancy. These hemodynamic alterations can be identified in apparently healthy women at different preclinical stages before manifestation of the disease, and SVR seems to be the most important predictive factor99,100. The fact that in patients with chronic hypertension there is an increased risk of FGR further supports the hypothesis that the maternal cardiovascular system plays a crucial role in the pathogenesis of abnormal placental function99,101.

Late fetal growth restriction

Compared with early FGR, late FGR is less closely associated with HDP, abnormal placental development and spiral artery remodeling. The main clinical challenge is its correct identification and diagnosis, firstly, due to the subtle clinical manifestations and, secondly, due to the fact that FGR might also exist in fetuses with size(abdominal circumference(AC) or estimated fetal weight(EFW))>10th percentile97,102,103. However, late FGR, with a prevalence of around 5-10%, is much more common than early FGR and thus has an important clinical impact97.

The association between late FGR and placental histopathological lesions is less evident than that in early FGR, and the differences compared with healthy

pregnancy are often very subtle ${}^{104}$ . Late FGR, compared with early FGR, shows less pronounced changes in uterine artery impedance ${}^{92}$ . In about one-third of all pregnancies,there is a worsening of uterine artery Doppler in the late third trimester ${}^{105}$ , suggesting that this late variation in uterine vascular resistance is not related to trophoblast invasion but is an effect of changes that involve the maternal cardiovascular system106. In these cases, there is a higher risk of low birth-weight percentile105. This observation explains the low predictive capacity of uterine artery Doppler velocimetry to identify late FGR and suggests the importance of maternal hemodynamic assessment in these cases. The second trimester may be optimal for maternal cardiovascular assessment for identification of patients at risk of developing late FGR13.

In pregnancies complicated by late FGR, maternal hemodynamic parameters do not show physiological cardiovascular adaptation, but show a flat, static pattern,with low CO and high SVR106.

Small-for-gestational age

When fetal size(AC or EFW) is below the 10th percentile,a priority is to differentiate between small-for-gestational age(SGA) and FGR. Some SGA fetuses might be consti-tutionally small but otherwise healthy and, consequently,at lower risk of adverse outcome. Identification of these pregnancies is important for their correct management and to avoid maternal anxiety and overtreatment. Thus,biophysical parameters other than size are required to differentiate SGA from FGR(e.g. fetal growth velocity,fetoplacental Doppler velocimetry, biomarkers)97,103,107.Maternal hemodynamics could play an important role in differentiating FGR from SGA. A normotensive pregnancy complicated by FGR is characterized by lower maternal HR, lower CO and higher SVR, while a pregnancy with a SGA fetus is characterized by a maternal hemody-namic profile similar to that of a healthy pregnancy ${}^{13,108}$ .Assessment of umbilical vein blood flow might provide even more detailed insights into the imbalance between fetal demand and maternal cardiovascular and placental availability 90,91,109,110

Key points

● Maternal hemodynamic parameters, such as CO and SVR, are associated with fetal growth and birth weight.

● Women with a hypodynamic circulation before and early in pregnancy are at higher risk of their pregnancy being affected by FGR.

● Early FGR is characterized by profound maternal hemodynamic changes, similar to those present in HDP with FGR.

● Late FGR is characterized by less pronounced mater-nal hemodynamic alterations, suggesting late maternal hemodynamic maladaptation to fetoplacental require-ments.

•Maternal hemodynamics, biomarkers and umbilical vein blood flow evaluation might provide additional

Consensus Statement

9

information to differentiate SGA from FGR, but further research is needed.

MATERN ALEMORYNAMICS AND CARDIOVASCULAR DISEASE LATER IN LIFE

There is growing evidence that the abnormal hemody-namic and echocardiographic findings that are common in women with HDP do not resolve following deliv-ery. Many women continue to be hypertensive in the immediate postnatal period, with some exhibiting signs of cardiac dysfunction16,17,111, and some are at risk of cardiovascular disease later in life112. Data from a recent randomized controlled trial(RCT) suggest that long-term cardiovascular health may be improved by close monitor-ing and effective control of BP in the immediate postnatal period113. Given these findings, increasingly, the hemody-namic assessment and management of women following HDP is considered important.

Risk of cardiovascular disease after HDP

The development of chronic hypertension after pregnancy complicated by HDP largely explains the increased risk of developing cardiovascular disease111,112. A meta-analysis showed that postpartum hypertension occurred five times more frequently in the first year following delivery in women affected by HDP112. The risk of HDP and/or chronic hypertension is related to obesity114, social deprivation115 and pre-existing or gestational diabetes113.The association of cardiovascular disease with specific risk factors after an episode of HDP remains subject to diverse interpretation. Dyslipidemia116, metabolic syndrome18 and accelerated rate of systematic atherosclerosis have been discussed regarding their possible link with an increased incidence of cardiovascular disease117. It seems likely that a cardiovascular system with subclinical impairment might be stressed by the demands during pregnancy, and/or that the endothelial stress of HDP accelerates damage of a dysfunctional cardiovascular system118.

The use of cardiovascular risk scoring does not improve prediction of postpartum cardiovascular complications,but, recently, a prediction model including maternal demographic characteristics, BP and echocardiographic parameters in the peripartum period identified women at risk of postpartum hypertension119,120.

Understanding factors that influence HDP for tailored proactive prevention later in life

HDP during pregnancy is a critical event affecting future cardiovascular health. Understanding the origin of HDP in pregnancy could help in proactively suggesting tailored preventive measures for the postpartum period and later in life. For instance, HDP associated with high placental oxidative stress, i.e. a high ratio between soluble fms-like tyrosine kinase-1(sFlt-1) and placental growth factor

(PIGF), are more frequently associated with FGR118. In the postpartum period, women who had HDP with lower values of PIGF showed worse cardiac structure, increased BP levels and higher lipid levels121. A recent meta-analysis confirmed that women who had early-onset PE, which is more frequently associated with FGR, had even higher risk of cardiovascular disease later in life122.

Whatever the cause and clinical phenotype of the disease, there is a dose-dependent effect between severity of HDP and likelihood of adverse cardiovascular outcome16. Preventive measures should be guided by a better understanding of the most likely cause of the HDP7.

Peripartum and postpartum echocardiographic

Profound echocardiographic changes are seen in most women with HDP, including increased left ventricular mass, cardiac remodeling and diastolic dysfunction113,123 Women with a history of PE also have altered cardiac structure and evidence of diastolic and myocardial dys-function in the early years after delivery 124,125. Despite this evidence, there are no recommendations regarding cardiac evaluation after HDP. However, women presenting with symptoms of dyspnea or signs of intravascular volume overload require echocardiographic evaluation123.

Compared to women with HDP and normal echocar-diography, those with HDP with severe left ventricular remodeling and diastolic dysfunction at echocardiogra-phy are more likely to develop chronic hypertension in the next decade126.

Optimal method and frequency of blood pressure measurement postpartum

According to a Norwegian population-based study, BP life-course trajectories remained higher in a HDP cohort compared to controls127. This study supports the inter-pretation of HDP not as causal, but rather as a marker of a pre-existing subclinical disease, and that diastolic BP does not return to‘normal’ levels during the postpartum period following HDP. Whatever the interpretation, lon-grudinal BP measurements should be undertaken in the postpartum period, as either home or scheduled ambu-latory BP monitoring. One trial proved that postpartum BP telemonitoring is effective, achieving 8-fold fewer hypertension-related readmissions128. It is well-tolerated by patients, is a better predictor of end organ damage than clinical measurement129 and may also reduce ethnic health disparities in postpartum care related to compliance.

Severe hypertension can occur postpartum, with the average latency period between delivery and BP levels that necessitate treatment being approximately 6 days130 These findings suggest that it is sensible to measure BP for at least the first 10 days postpartum130. Given the significant diurnal variation in BP in women with HDP, with BP climbing in the afternoon and evening in approximately 50% of women, twice-daily readings would seem appropriate131.

10

Consensus Statement

A trial of postpartum BP self-monitoring and self-management via remote medication advice and feed-back in women who experienced HDP demonstrated high acceptability, adherence and accuracy, and a significant improvement in BP control132. BP control was better whilst on treatment, but, more importantly, the diastolic BP was on average 4.5 mmHg lower 6 months postpar-tum, approximately 3 months after stopping medication.A follow-up study 4 years postpartum demonstrated that the diastolic BP was more than 7 mmHg lower in those originally randomized to postpartum BP self-management vs those treated with standard care133. This is highly sug-gestive of a window of opportunity to optimize long-term cardiovascular health by optimal monitoring and man-agement of BP postpartum.

Optimal antihypertensive medication

Optimal management strategies once hypertension and/or cardiovascular dysfunction has been confirmed postpar-tum remain largely undetermined. It is likely that the findings from a furosemide RCT could be adopted to treat women with hypervolemic hyperdynamic late preterm or term HDP, using a 5-day course of 20-mg oral furosemide134. However, no specific guidelines are avail-able for long-term prevention or therapeutic intervention,except for the American Heart Association's recommen-dation regarding HDP as an additional risk factor to guide prescription of statins as a risk-reduction measure135.

Angiotensin-converting enzyme(ACE) inhibitors were tested in a double-blind randomized placebo-controlled trial in the postpartum period in patients who had early-onset PE136. This trial fell short of proving a reduction in SVR, yet patients in the treated arm showed lower diastolic BP, better diastolic function and improved left ventricular remodeling at 6 months postpartum.Obstetrician-gynecologists, physicians and primary-care doctors should exploit the‘fourth trimester’ to help improve the future cardiovascular health of women who have been exposed to HDP.

Key points

● Maternal hemodynamic alterations present during HDP may persist in the postpartum period and predispose women to increased cardiovascular risk later in life.

● Women with a history of HDP and symptoms of dyspnea or signs of volume overload should undergo an echocardiographic evaluation.

● Longitudinal BP measurements, obtained by either home or ambulatory monitoring, should be carried out in the postpartum period in women with a history of HDP.

● In women with a history of HDP, postpartum monitoring of BP should continue for at least the first 10 days and should be performed at least twice per day.

● Women who experienced HDP should be counseled proactively regarding life-style changes(e.g. diet,smoking habit, exercise).

IMPLICATIONS FOR PREDICTION,PREVENTION AND MANAGEMENT

The association between HDP and FGR and maternal changes in cardiovascular function, both before and after development of the clinical syndrome, presents an opportunity for using assessment of maternal hemodynamics in the clinical setting.

Potential for prediction

Despite evidence of maternal cardiovascular maladapta-tion in pregnancies destined to develop HDP and FGR,prediction of these conditions in early pregnancy is not feasible given the wide overlap between physiological and pathological changes. The performance of first-trimester prediction of PE using biomarkers(PlGF), uterine artery Doppler and maternal characteristics(BP and body mass index(BMI)) presents a promising‘proof-of-principle’algorithm, and assessment of second-trimester uterine artery Doppler has been well described137.

Prevention

Given the relationship between high SVR prior to pregnancy47 and risk factors such as high BMI and low PV138,139, it is tempting to consider that optimizing maternal cardiovascular function prior to pregnancy might reduce the risk of HDP and FGR. Exercise in women with previous PE improves cardiovascular function, returning it to that of a sedentary woman140,and results from a meta-analysis suggest that exercise prior to pregnancy reduces the incidence of placental syndromes141. Non-pharmacological vasoactive dietary nitrates might reduce BP in hypertensive pregnant women136. No study has examined the potential for nitrates and exercise in reducing the risk of HDP or PE in high-risk women, though the rationale for this is compelling. Other treatments, such as low-dose aspirin142, have been proposed for the prevention of PE;however, with the relationship to maternal hemodynamic parameters being unclear, their description is beyond the scope of this document.

Management of established HDP and/or fetal growth restriction

Despite major pharmacological advances in the treatment of hypertension in the non-pregnant population, treat-ments for hypertension in HDP and PE have remained largely unchanged over the last 50 years. Adrenocep-tor antagonists(such as labetalol) and the competitive alpha-adrenoceptor blocker, doxazosin, calcium channel antagonists(such as nifedipine), vasodilators(such as hydralazine) and centrally acting dopamine antagonists(such as alpha-methyldopita) are the mainstay of anti-hypertensive therapy during pregnancy. The definitive treatment for HDP and PE is delivery; hence, iatrogenic preterm birth is common, usually indicated because of

Consensus Statement

11

uncontrolled maternal hypertension, organ dysfunction or risk of seizures.

Therapy for HDP principally involves strategies to lower BP. This can be achieved by one or both of two mechanisms: by causing vasodilation and, thus,decreasing SVR, or by decreasing CO. Currently, these treatments are used variably with respect to the timing of onset of HDP and the presence of FGR. Knowledge of the two phenotypes of HDP, resistance-dominant and volume-dominant, could provide a potential opportunity for targeted antihypertensive therapy that seeks to compensate for the underlying cardiovascular deficit,although it is important to note that targeting BP in PE may compromise a growth-restricted fetus15. As FGR frequently coexists with PE, especially at earlier gestational ages, at least theoretically, it is important for CO and BP to be maintained in order not to compromise the uteroplacental circulation.

The pathophysiological concept of a bimodal hemody-namic pattern of HDP has important clinical implications.The BP-lowering pharmacological mechanisms of differ-ent antihypertensive drugs differ, offering opportunities for phenotype-specific treatment of hypertension in preg-nancy143-145. Calcium channel blockers predominantly reduce arteriolar hypertonia, resulting in lower SVR with a subsequent rise in CO146,147. Beta-blocking agents are less active in vascular resistance-dominant HDP and, for this reason, clinical management protocols have been reported proposing the replacement of beta blockers by calcium channel blockers after 24h in non-responsive cases148. Treatment of women with HDP with beta block-ers, including labelatol, has been associated with lower neonatal birth weight149; therefore, their use should be considered carefully in cases of HDP with poor fetal growth. RCTs are currently running to evaluate the gesta-tional and neonatal outcome of targeted antihypertensive treatment in resistance-dominant or volume-dominant HDP143,150.

Discrimination between resistance-dominant HDP and volume-dominant HDP also challenges general guide-lines recommending a‘one-for-all’ pharmacological treat-ment151 and stimulates further exploration of the role of targeted pharmacological treatment in both latent and clinical stages of disease. New and currently unex-plored management options include treatment with diuretics in cases of volume-dominant HDP152 and/or NO donors targeting the activated endothelium of aret-rial, microcirculatory and venous parts of the circu-lation153,154. A previous observational study suggests that vasodilator therapy improves birth weight and growth velocity in FGR155. More studies are required to identify whether targeting therapy in HDP in this way achieves better BP control or improved obstetric outcome.

Additional preventive and therapeutic approaches include the possible immune-modulation impact of low-molecular-weight heparin in HDP associated with FGR156.

Sildenafil prolonged gestation by a non-significant 4 days157 and its use in clinical practice has been curtailed due to findings of increased neonatal death due to pulmonary hypertension in trials in pregnancies affected by severe early-onset FGR158,159. No benefit in terms of prolongation of gestation has been reported from the use of esomeprazole, pravastatin160,161 or antithrombin162.There is evidence to support the prolongation of gestation in expectantly managed PE with administration of metformin, although more studies are needed163. NO donor S-nitrosoglutathione has demonstrated efficacy in improving proteinuria and arterial and platelet function in women with severe early-onset PE, suggesting a potential disease-modifying mechanism of action153,164,165.

Key points

● Maternal hemodynamic changes precede the develop-ment of clinical symptoms in pregnancies with PE and FGR, opening a window of opportunity for prediction and prevention.

● Exercise, dietary nitrates and control of BP prior to and in early pregnancy may improve hemodynamic indices but have not been shown to reduce the incidence of PE and FGR in women at high risk.

● Knowledge of the two cardiovascular phenotypes of HDP could provide a potential opportunity for targeted antihypertensive therapy to replace a‘one-size-fits-all’pharmacological approach to HDP.

● Calcium channel blockers are preferred in women with high SVR and low CO(usually PE/HDP associated with FGR,i.e. the resistance-dominant phenotype).

● Beta-blocking agents should be used with care in cases of HDP associated with FGR.

AREAS FOR RESEARCH

From the evidence outlined above, it is clear that the assessment of maternal hemodynamics adds information to current knowledge on the pathophysiology of gestational complications. However, it is unclear to what extent these assessments are clinically useful and cost-efficient. Further research is required to address the following areas.

Applicability in clinical practice

Future research should focus on identifying the most effective techniques and maternal hemodynamic parame-ters, used either individually or in combination, and on establishing their normal reference ranges27. The potential value of assessing the currently unexplored pathophysi-ological mechanism of the maternal venous system and body water volumes, independently or in combination with cardiac and arterial function, should be investi-gated85. Whether hemodynamic testing is better limited to a selected high-risk population or offered to all pregnant women should also be explored.

12

Consensus Statement

Screening for gestational complications

Prospective longitudinal studies that include preconcep-tional data are required to improve our understanding of changes in maternal hemodynamics and to clarify whether, in pregnancies affected by HDP, the car-diovascular profile is altered due to maladaptation in the index pregnancy, or pre-existing pathology in the cardiovascular system is unmasked by pregnancy78,166.The feasibility and relevance of preconceptional screening remains to be explored.

Little is known regarding changes in maternal hemodynamics in the preclinical phase, among pregnant women at risk of developing PE who are taking low-dose aspirin, calcium supplements and/or vitamin C. Furthermore, newly emerging screening strategies using biophysical parameters only should be evaluated167.Future prognostic studies are required to evaluate the optimum structure and timing of a screening program that could help to identify women at risk of developing HDP and pregnancy complications. The program should use current available reference ranges for both maternal cardiac function32 and arterial stiffness22. They should report parameters appropriately adjusted for confounding factors and identify optimum timing of, and parameters for, screening.

PE is a risk factor for short- and long-term cardiovascular-variance. Research is required to identify the optimum postpartum screening program that could identify women at risk of long-term cardiovascular dysfunction and guide future management in subsequent pregnancies 12,16,18.

Few studies have examined changes in maternal hemodynamics among pregnant women with multiple pregnancy or reduced fetal movements, those undergoing induction of labor and those who require regional anesthetics at the time of delivery. Future studies should provide guidance regarding the benefits of maternal hemo-dynamic assessment in the clinical setting in these cases.

Diagnosis of medical disorders

Assessment of maternal hemodynamics, including venous function and volume homeostasis, is useful to discriminate between GH, PE and normotensive FGR,85. This approach can also help distinguish volume-dominant from resistance-dominant GH6. However, the feasibility and applicability of these methodologies require further evaluation.

The use of point-of-care/near-patient testing and con-tinuous monitoring is increasing, revolutionizing maternal healthcare. Future investigators should report maternal hemodynamic parameters appropriately adjusted for con-founding factors and identify optimum timing, of and parameters for, screening.

Gestational diabetes is noted to be associated with maladaptation of the cardiovascular system in pregnancy.Future studies are required to evaluate the optimum timing for screening, correlate findings to clinical outcomes and critically evaluate the role of metformin therapy and modulation of arterial stiffness ${}^{22,168-172}$ .

Management of HDP

Volume-dominant and resistance-dominant HDP are two different pathophysiological phenotypes ${}^{76,106,173}$ . It remains to be determined whether targeted antihyper-tensive treatment may improve obstetric and neonatal outcome ${}^{150}$ . Large RCTs are needed to evaluate the poten-tial therapeutic benefit of targeting variable components of the maternal hemodynamic maladaptation syndrome observed in pregnant women with HDP. The algorithmic model that combines the Z-score of multiple parameters of maternal hemodynamics will need further validation to assess whether it could guide treatment and assess the treatment response ${}^{174,175}$ . Hemodynamics-assisted mon-itoring of gestational complications might be useful to improve obstetric and neonatal outcome, but this approach has yet to be validated106,176. The imple-mentation of maternal hemodynamic assessment is an opportunity to explore the application and effectiveness of currently unexplored antihypertensive treatments, such as diuretics ${}^{176-178}$ and nitrates ${}^{179-181}$ .

Prevention

As the subpopulation of younger parturients with morbidities is on the rise, hemodynamic assessment provides opportunities to initiate prevention strategies with the aim of improving maternal cardiovascular function before conception ${}^{182}$ . The same applies to women with a history of PE, in whom prevention strategies could potentially be initiated during the interpregnancy interval ${}^{140}$ . The clinical relevance of these interventions remains to be explored.

Obesity is associated with low-grade chronic inflamma-tion in adipose tissue, diastolic dysfunction and arterial stiffness183; studies should examine how this contributes in general to vascular dysfunction and, more specifically,to the pathogenesis of hypertension and vascular stiffen-ing ${}^{184,185}$ .

CONCLUSION

Maternal hemodynamic assessment provides additional clinical information that is useful for management of pregnancies complicated by HDP and/or FGR. Moreover,it opens a window of opportunity for prediction and prevention of maternal hemodynamic maladaptation,which may benefit both the index pregnancy and future maternal cardiovascular health.

CONSENSUS STATEMENTS

● After 20 weeks of gestation, assessment of maternal hemodynamics should be performed with the woman in a left lateral position.

- Different techniques of maternal hemodynamic evalua-tion cannot be used interchangeably.

Consensus Statement

13

● Maternal hemodynamics differentiates two HDP phe-notypes: resistance-dominant and volume-dominant.

● Women with resistance-dominant HDP(usually HDP associated with FGR) should be treated with a vasodilator, such as calcium channel blockers.

● Women with volume-dominant HDP(usually HDP with appropriate-for-gestational-age fetal growth)should be treated with beta-blocking agents.

● Maternal hemodynamic evaluation might be useful in preconception and preclinical stages of HDP as an opportunity for prediction and prevention, but further research is required.

● An echocardiographic assessment should be performed in women with a history of HDP and symptoms of dyspnea or volume overload.

● Maternal hemodynamics should be evaluated in the postpartum period in women with a history of HDP, to identify those at increased risk of cardiovascular disease later in life.

● In women with a history of HDP, longitudinal BP measurements are recommended in the postpartum period.

● Women with a history of HDP should be counseled proactively regarding life-style changes.

AUTHORS

T.Stampalija,Unit of Fetal Medicine and Prenatal Diagnosis, Institute for Maternal and Child Health,IRCCS Burlo Garofolo, Trieste, Italy; and Department of Medical, Surgical and Health Science, University of Trieste, Trieste, Italy

C.Lee®,Centre for Fetal Care, Department of Obstetrics and Gynaecology, Queen Charlotte's and Chelsea Hospital, Imperial College Healthcare NHS Trust,London, UK and Department of Metabolism, Digestion and Reproduction, Imperial College London, London, UK T.Ghi®, Catholic University of Sacred Heart Rome,Department of Women and Child Health, Fondazione Policlinico Universitario Astogino Angemelli IRCCS, Rome,Italy

J.Cornette, Department of Obstetrics and Gynecology,Division Obstetrics and Fetal Medicine, Erasmus MC,University Medical Center, Rotterdam, The Netherlands W. Gyeselaers, Faculty of Medicine and Life Sciences,Limburg Clinical Research Center, Hasselt University,Diepenbeek, Belgium; and Department of Obstetrics&Gynecology, Ziekenhuis Oost-Limburg, Genk, Belgium E.Ferazzi, Obstetrics Unit, Department of Woman Child and Newborn, Fondazione IRCCS Ca' Granda,Ospedale Maggiore Policiolic Milan, Italy; and Depart-ment of Community and Health Sciences, University of Milan, Milan, Italy

T.Mousa, Maternal and Fetal Medicine Unit, University of Leicester, Leicester, UK

M.Spaanderman, Department of Obstetrics and Gynecol-ogy, Maastricht University Medical Center, The Nether-lands; and Department of Gynaecology and Obstetrics,

Radboud University Medical Centre, Nijmegen, The Netherlands

B.Thilaganathan D, Fetal Medicine Unit, St George's University Hospitals NHS Foundation Trust, University of London, London, UK; and Molecular and Clinical Sciences Research Institute, St. George's University of London, London, UK

H. Valensise, Department of Surgical Sciences, University of Rome Tor Vergata, Rome, Italy; and Department of Obstetrics and Gynecology, Policlinico Casilino, Rome,Italy

Collaborators

We would like to thank the following members of the International Maternal Hemodynamic Group for their critical revision and contribution to this document:

J.J.Duvekot, Department of Obstetrics and Gynecology,Erasmus MC University Medical Center, Rotterdam, the Netherlands

C.Ghossein-Doha, Department of Obstetrics and Gyne-cology, Maastricht University Medical Centre, Maas-tricht, the Netherlands; and Research School GROW,University of Maastricht, Maastricht, the Netherlands C.McEniery, Division of Experimental Medicine and Immunotherapeutics, University of Cambridge, Cam-bridge, UK

F.Mecacci, Department of Obstetrics and Gynecology,Department of Experimental of Experimental, Clinical and Biomedical Sciences, Careggi University Hospital, University of Florence, Florence, Italy

G.P.Novelli, Division of Cardiology, Department of Medicine, Tor Vergata Polyclinic, Rome, Italy

B. Vasopollo, Department of Surgical Sciences, Tor Vergata University, Rome, Italy; and Department of Obstetrics and Gynecology, Policlinico Casilino Hospital,Rome, Italy

I. Wilkinson, Division of Experimental Medicine, Uni-versity of Cambridge, Addenbrooke's Hospital, Cam-bridge, UK

CITATION

This Consensus Statement should be cited as:‘Stampalija T, Lees C,Ghi T, Cornette J, Gyselaers W, Ferrazzi E,Mousa T, Spaanderman M, Thilaganathan B, Valensise H and Collaborators. ISUOG Consensus Statement on maternal hemodynamic assessment in hypertensive disor-ders of pregnancy and fetal growth restriction. Ultrasound Obstet Gynecol 2025. doi:10.1002/uog.70040.

REFERENCES

1. Capeless EL, Clapp JF. Cardiovascular changes in early phase of pregnancy. Am J Obstet Gynecol.1989;161:1449-1453.

2. Clapp J F, Caplees E. Cardiovascular function before, during, and after the first and subsequent pregnancies. Am J Cardiol. 1997;80:1469-1473.

3. Cornette J, Roos-Hesselink JW. Normal cardiovascular adaptation to pregnancy. Evidence-Based Cardiology Consult. Springer; 2014:423-432.doi:10.1007/978-1-4471-4441-029

14

$$\text{Consensus Statement}$$

4. de Haas Sghosin-Doha C, van Kujish SMJ, van Drongenspan, JoLteran. A Physiological adaptation of maternal plasma volume during pregnancy; a systematic and molecular dynamics.

5. Duevek Jr.,Chemix E, Pieters FA, Menheere PP, Peeters LH. Early pregnancy changes in hemodynamics and volume homostas are consecutive adjustments triggered by a primary fall in systemic vascular tone. Am J Obstet Gynecol.1993;169:1382-1392.

6. Gyrelos W. Hemodynamic pathways of gravitational hypertension and preprecam-sia. Am J Obstet Gynecol. 2022;226:5985-51005.

7. Melchori K, Gergione V, Thilaganathan B. The placenta and preclampsia-villar vs. Jim J Obstet Gynecol. 2022;226:5954-5962.

8. Bosio PM, McKenna II, Proroy R, O'Herliy C. Maternal hemodynamics in hypertensive disorders of pregnancy. Obstet Gynecol. 1999;94:978-984.

9. Bamfo JE, Kametas NA, Chambers JB, Niiculades KH. Material cardiac function in fetal growth-related non-growth-restricted small-for-gational aerogen amplitudes. Uncertainty. Subsordt Obestung Gynecol. 2007;29:51-98.

BSSHP classification, diagnosis, and management recommendations for interma-tional practice. Hypertension. 2018;72:44-23.

11. Stott D, Bolten M, Salman M, et al. Maternal demographics and hemodynamics for the prediction of fetal growth restriction at booking, in pregnancies at high risk for placental insufficiency. Acta Obstet Gynecal. 2015;69:329-338.

12. Mulder EG, Ghosin-Doha C, Cauffman E, et al. Preventing recurrent pycloperlinea by tailored treatment of nonphysiologic hemodynamic adjustments to pregnancy. Hypertension.2021;77:2045-2053.

13.Vasapollo B, Valensise H, Novelli GP,et al. Abnormal maternal cardiac function precodes the clinical manifestation of fetal growth restriction. Ultrasound Obstet Gynecol. Gynecol.2004;24:23-29.

14. Tay J, Foo L, Masini G, et al. Early and late prelancapsite are characterized by high cardiac output, but in the presence of fatal growth restriction, cardiac output is low: insights from a prospective study. Am J Obstet Gynecol. 2018;218:517,e117.e12.

15. Vasapillo B, Zulline S, Novillé G, et al. Pulant hemodynamics from preconception to delivery: research and potential diagnostic and therapeutic implications: position statement by Italian association of precellaum and Italian society of periantional Medicine. Am J Perintanol. 2024;41:49919-2003.

16. Khilcror K, Thilorahan B, Giongere V. et al. Hypertensive disorders of pregnancy and future cardiovascular health. Front Cardiovasc. Med.2020;75:19.

17. Melchiorre K, Thorsubland G, Liberati M, Thalanobithan B. Precampsia is associated with persistent postpartum cardiovascular impairment. Hypertension.2011;507:789-715.

18. Ghossein-Doha C, Van Neer J, Wissink B, et al. Pre-clampsia: an important risk factor for asymptomatic heart failure. Ultrasound Jyncolus.Gycol.2017;49:143-199.

19. Browers L, van Neer J, Wissink B, et al. Recurrence of pre-clampsia and the risk of future hypertension and cardiovascular disease: a systematic review and meta-analysis. BJOG.2018;125:1624=1654.

20. Sharman JE, Avol AP, Baulmann J, et al. Validation of non-invasive central blood pressure driven by AERETTER Y of artery cluster mass for consensus statement on protocol standardization. Eur J Heart. 2017;38:2805-2812.

21.Aldridge E, Molen J, Verburg PE, et al. Agreement of anoid and oscillatory blood pressure devices used in pregnancy. Hypertension 2019;17:43-48.

22. Anwres AR, Néelom, V., Bleng Ver, P, et al. Agreement of anoid and oscillatory blood pressure devices used in pregnancy. Hypertensancy. 2019;17:43-48.

23. Fo FL, McEnesium LC, Lee C,Khall A, International Working Group on Maternal Hemodynamics. Assessment of arterial function in pregnancy: recommendations of the International Working Group on Maternal Hemodynamics. Ultrasound Obstet Gynecol. 2017;52:34-331.

24. Marti ND, Stampal Jasi, R Tosti R, Oli et al. Beddeic cardiovascular material interrogation in the first timestep to predict different phenotypes of hypertensive disorders in pregnancy. Pregnancy Hypertensions. 2016;6:300-305.

25. Perry H.,Guretier J, Binder, J. Thiluganhar B, Khali A. Materal arterial stiffness in hypertensive pregnancies with and without small-for-gestational age-neon. Ultrasound Obstet Gynecol. 2020;56:54-40.

26. Huavater A, Gamone T, Savelli H-4G, et al. The association between pccalperia and atrial stiffness. J Hypertension 2012;30:17:33.

27. Bilj RC, Valensise H, Novelli GP, et al. Methods and considerations concerning cardiac output measurement in pregnant women: recommendations of the International Working Group on Maternal Hemodynamics. Ultrasound Og Bynecol.2019;54:35-50.

28.Riosa, A Conterjee, J. John MR, et al. Quantitative cardiovascular magnetic resonance in pregnant women: cross-sectional analysis of physiological parameters throughout pregnancy and the impact of the suppositione. J. Cardiovasc Magn Reson.2011;13:31.

29. Humphreis A, Mirališraa, SAi Mili, Sa Trco, Thompson J.McD, Stone P. The effect of supine positioning on maternal hemodynamics during late pregnancy. J. Matern Fetal Neonatal Med. 2019;32:3923-3930.

30. Van oppen A, Van Oper et al. Brovell D, Brueck JJ, Brube HW, OF use of cardiac index in pregnancy is it justified? Am J Obstet Gynecol. 1995;173:929-928.

31. Chantler PD,Clements RE, Sharp L, George KP,et al. The influence of body size on measurements of overall cardiac functions. Am J Physiol Heart Cry Physiol.2005;289:H2059-H2065.

32. Vinayagu D, Thilaganathan B, Stirrup O, Mantovani E, Khalil A. Maternal hemodynamics in normal pregnancy: reference ranges and role of maternal characteristics. Ultrasound Obstet Gynecol. 2018;51:665-671.

33. Dler RA, Pyier MC, Jl red, AR, et al. Comparison between pulse waveform analysis and thermodulation cardiac output determination in patients with severe pre-clampsia. Br J Anaestb. 2011;106:77-81.

34. Brogly N, Schiraldi R, Puert L, Anet al. Pulse contour analysis calibrated by Trans-Polarum-torhermedlution(Pco Plus) for the perioperative management of a casaean section in a patient with severe cardiomyopathy. Braz J Anestbiol.2016;66:329-332.

35. Romagano M,Louin-Jacques A, Quinones J, et al. Is there a role for cardiac magnetic resonance imaging during pregnancy? J Matern Fetal Neonatal Med.2020;33:558-563.

6.Belfort MA,Roey,R Sadea GR,Moise KJ. Rapid echocardiographic assessment of left and right heart hemodynamics in critically ill obstetric patients. Am J Obstet Gynecol. 1994;171:884-892.

37. Cornette J,Laker J,Seefley B,et al. Validation of maternal cardiac output assessed by transformacic echocardiography against pulmonary artery catheterization in severely still pregnant women: prospective comparative study and systematic review.Ultrasound Obstet Gynecol. 2007;29:51-31.

38.Mena J,Arosonin C,Hernander A,et al. Left ventricular diastolic function in normal human normal cancer. Circulation. 1999;99:511-517.

39.Griffiths SE, Waig D, Dennis A AT. Focused transthoracic echocardiography in obstet B. Acad.18;2018;37:21-27.

40 KCM Cemccu, B. Steady, C. Stamant, C. Measurement of cardiac output in normal pregnancy by a noninvasive two-dimensional independent Doppler device. Aust N Z J Obstet Gynecol. 2009;49:142-144.

41. Fariana, S. Teruzi, C. Cantadori, G. et al. Noninvasive cardiac output measurement by inert gas rebreast in suspected pulmonary hypertension. Am J Cardiol.2014;113:54-565.

42. Mahanae Advu, BeERtr TR, Wilkinson IB, Lees CC, McEniery CM. A longitudinal study of maternal cardiovascular function from preconception to the postpartum period.J Hypertens.2014;32:849-856.

4.Scardo JA,Ellilges, R.,Vennestl ST,Chauhan SP. Validation of bioimpedance esti-

44. Vinagamav,D Bowe,Shean Efe,E, Thilaganathan B, Khalil A. Non-invasive hemodynamic monitoring in pregnancy: a comparative study using ultrasound and biorectance. Fetal Dage Ther 2017;41:273-282.

Aulur JOC, Torres M,upas L, Cardia M, Openo MM, et al. Clinical evaluation of the flucortrac/Vigolide system for continuous cardiac output monitoring in patients undergoing regional anaheyses for elective cesarean section: a pilot study. Clinics(Sao Paulo) 2010;65:793-798.

4.Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet. 1986;1:307-310.

47. Flouin, Collins A, McEniery M, et al. Preconception and early pregnancy maternal haemodynamic changes in healthy women in relation to pregnancy viability. We Rufin, Res. 2017;132-995-892.

Vison, B. Sehtens, A. Eninier, B. Exin, K. Gyelseans W. Why non-invasive maternal hemodynamics assessment is clinically relevant in early pregnancy: a literature review. BMC Pregnancy Childbirth. 2016;16:302.

49. Maharazusk A, Exert TR, Wilkinson AB, Lees CC, McEniery CM. Maternal cardiovascular changes from pre-invasive pregnancy to very early pregnancy. J Hypertens.2012;30:2168-2172.

50.Spanderman ME, Wilkes C, Hooks AP, Ekhart TH, Peeters LL. The effect of pregnancy on the compliance of large arteries and veins in healthy porous control subjects and women with history of preclampsia. Am J Obstet Gynecol.2003;18:1276-1266.

5. Chapman AB, Zamaviou, Woodson B, Vanseeh See, et al. Systemic and renal hemodynamic changes in the late phase of the menastral cycle mimic early pregnancy. Am J Biophys.1997;273:5777-F782.

52. Chapman AB, Abraham AB, Western Mac 3, et al. Temporal relationships between hormonal and hemodynamic changes in early human pregnancy. Kidney Int.1998;54:2056-2063.

35. Robson SC, Hunter S, Boys JR, Dunlop W. Serial study of factors influencing changes in cardiac output during human pregnancy. Am J Phys.1989;256:H1060-H1065.

54. Poppas A, Sheffro S, Kocarci CE, et al. Serial assessment of the cardiovascular system in normal pregnancy. Role of arterial compliance and pulsatile arterial load.Circulation.1997;95:2407-2415.

5.Liu, LANx, Arzia Z. Maternal cardiac metabolism in pregnancy. Cardiacov Res.Circulation.1997;95:2407-2415.

56. Mulder E, de Haas S, Mohsen Z, et al. Cardiac output and peripheral vascular resistance during normative and hypertensive pregnancy- a systematic review and meta-analysis. BJOG/2022:129:696-707.

57. Fastering RL, Benetti TJ, Schnetler BC, Millard SP. Maternal hemodynamics in and preclamp energetic: a longitudinal study. Obstet Gynecol.1990;761061-1069.

5. Masini G, Ben AB, OfLor, Cette J, et al. Cardiac output changes from prior to pregnancy to post partum using two non-invasive techniques. Heart. 2019;105:715-720.

9. Rubnabem L, Janusson BJ, Van Dijk AP, J et al. The relation between venous reserve capacity and low plasma volume. Reprod Sci. 2008;15:604-612.

60. Estensen ME, Beires NO, Grothim E, Gait al. Altered maternal left ventricular contractially and function during normal pregnancy. Ultrasound Obstet Gynecol.

61. Savu O, Jurcrot R, Giucsa S, et al. Morphological and functional adaptation of the maternal hand during pregnancy. Circ Cardiovasc Imaging. 2012;5:289-297.

63. Kalva Youssel, A Maruzzi, E et al. Maternal cardiac function in normal twin pregnancy: a longitudinal study. Ultrasound Obstet Gynecol. 2011;38:575-580.

3. Kametas NA, McAlufre K, Amplam E, Chambers J, Nicolaides KH. Maternal cardiac function in twin pregnancy. Obstet Gynecol. 2003;102:806-815.

Consensus Statement

15

6. Robson SC, Hunter S, Boys R, DjunLop. W. Hemodynamic changes during twin pregnancy. A Depler and M-mode echocardial growth. A Jw J. Obstet Gynecol. 1989;161:1273-1278.

65.Thomsen JK, Fogh-Andersen N, Jaszczak P. Arial natriuretic peptide, blood volume, altoadense, and sodium execution during train pregnancy. Acta Obstet Gynecol Scand.1994;77:130.

66. Ghi T,Dall Asta A, Franchi L, et al. The effect of chorionicity on maternal cardiac adaptation to uncomplicated twin pregnancy: a prospective longitudinal study.Fatal Diagn Tber. 2019;45:394-402.

67. Ghi T, Esposti DD, Montagui E, et al. Maternal cardiac evaluation during uncomplicated twin pregnancy with emphasis on the diastolic function. Am J Obstet Gynecol. 2015;213:376:1-376.8.

86. Farsetti D, Pometri F., Novelli GP, et al. Longitudinal hemodynamic evaluation of uncomplicated twin pregnancies according to chronicity: physiological cardiovascular dysfunction in monochoric twinary pregnancy. Ultrasound Ostelovic Gynecol.2024;63(2):198-205.

69.Ghi T, Esposi DD, Montagui et al, Post-partum evaluation of maternal cardiac function after severe clamparcia. J Mater Fetal Neonatal Med.2014;276:697-76.

70.Nunez,Eulhu,Arozao MG,et al.Materal cardiac function in twin pregnancy at 19:21 weeks: generation Ultrasound Obstet Gynecol. Scannol. Science.

11. Redman C.Wang S, Recent Li. Latest advances in understanding preeclence. Science.2005;308:1592-1594.

72.Steegers EAP, von Dadelsen P, Duveek PJ, Jojbaren P, Regrampis. Lancet. Lancet

73. Raymond D, Peterson E. A critical review of early-onst and late-onset precampials. Obstet Gynecol Surv.2011;66:497-506.

75. Valenisei H, Vasapolo B, Gagliard G, Novelli GP. Early and late preclumpia two different maternal hemodynamic states in the latent phase of the disease.Hypertension. 2008;52:873-880.

75. Ferazzi Z, Zulino S, Tsupblai T, et al. Redside diagnosis of two major clinical phenotypes of hypertensive disorders of pregnancy. Ultrasound Obstet Gynecol.2016;48:224-231.

76. Razzizzi, Yamata Tralon, L.; et al. Matem hemodynamics: a method to classify hypertensive disorders of pregnancy. Aw J Ostol Gynecol.2018;218(1):124e-124.e114.

77. Wieling W, Jardine DL, de Lange FJ, et al. Cardiac output and vasodilation in the vasagrolvage response: An analysis of the classic papers. Harnt Rydth.

78. Rang S, van Monfrans GA, Wolf, H. Serial hemodynamic measurement in normal pregnancy,producampia, and intrauterine growth restriction. Am J Obstet Gynecol.2008;1981;59:e1-9e.

79. Amaral LM, Cunningham MW, Correlusi, LC DaLC. Rae preBampel, Caxal long-term consequences for vascular health. Vasc Health Risk Manag.Socai,2015;11:403-415.

80. Owugunom, SM Winnya G, Wang X, et al. Preclampusia across pregnancies and risk factors: findings from a high-risk end US risk. J Am Heart Assoc, Joc2018;11:091626.

81. Oguwom SM, Chen X, Mitra S, et al. Interconception care for primary care providers: consensus recommendations on preconception and postpartum management of reproductive age-patients with medical contobacterials. Mayo Clin Proc Optimal Out of 2005;21:87-802.

82.Mendez-Castro C, Rascher W, Hartner A. Intraturate growth restriction: ApoFucic and cardiovascular diseases later in life. Mol Cell Pediatr. 2018;5:870-

83 James, Ljut White, LGurartt W. Grie-Beep: J.J. Petrolal. 2010;21:363:378-36.

84. Mor G, Aldo Alpero AB. The unique immunological and microbital aspects of pregnancy.Nur Resonamal. J. 2017;469:482.

85. Gyaleswren, Vonck S, Stelans Al, et al. Gestational hypertensive disorders show unique patterns of circularity deterioration with ongoing pregnancy. Am J Physiol Repergf 1et Compial Physiol.2019;316:R10-8211.

86.Myburgh JA, Brown M, Yhong ME. Resuscitation fluids. N Engl J Med 2018;369:1243-1251.

87.McDermov M, Miller EC, Kundek T, Hurp D, Bushnell D, Creeplamps:association with posterior reversible encephalopathy and stroke.Stroke.2018;49:524-530.

88 Gyles W. Maternal nervous hemodynamic dysfunction in therapeutic gestational hypertension and implications in implications of pregnancy. Jialcue in Mergon, J. Clue Med. 2019;8:335.

89. Perry H, Lehmann of Mantovani, T. Thilaganathan, Bahl K, Correlation between central and uterine hemodynamics in hypertensive disorders of pregnancy.Ultramodal Obstet Gynecol. 2019;49:58:63.

90. Valensel F, Harst Dopit, Petti F, et al. The cardiac-fetal-plateular unit for fetal growth inel flow rate is linked to the maternal cardiac profile in fetal growth restriction. Am J Obstet Gynecol. 2023;228:122:02:12.72

11. Barbieri M, D. Martino D, Ferrzi E, Stampani T. Umbil v. Extremation of Jesttia and State-of-the-art. J Clin Ultrasound.2023;51:318-325.

92. Bosresen L, Pipen Borgen R, Vercruyse L, Romero R. The"Great Obstetial Syndromes" are and disorders of deep placenta. Am J Obter Gynecol. 2011;204:193-201.

9. Mecacci F, Avagliano L, Lisi F, et al. Fetal growth restriction: does an integrated maternal hemodynamic-placental model fit better; Repol Sci.2021;28:2422-2435.

94. Bonamy A-KE, Parikh N, Nictingu, SlUDsson JF, Ingelson E. Birth, Macrophys and subsequence risks of maternal cardiovascular disease. Circulation.2011;224:2839-2846.

95. Ray JG, Vermeulen MJ, Schull MJ, Redelmeier DA. Cardiovascular health after maternal placental syndromes(CHAMPS): population-based retrospective work.Lancet.2005;366:1797-1803.

9. Gordijn SJ, Beune IM, Thilaganath B, et al. Consensus definition of fetal growth restriction: a Dephci procedure. Ultrasound Obstet Gynecol. 2016;48:333-339.

98. Lescas,Cangulai, T.Baschat,A et al. IsUOGR Practice Guidelines: diagnosis and management of small-fastilal-geral fetus and fetal growth restriction.Ultrasonal Obsevary Gynecol. 2016;56:298-312.

88Duev JJ, Cheric ChEs, Petricz F, FA, et al. Maternal volume homeostasis in early pregnancy in relation to fetal growth restriction. Obstet Gynecol.1995:18:367.

9. Vasapolo B, Novelli GP, Farreni D, Valensise H. Maternal peripheral vascular resistance at midtose generation of hypertensive hypertension as a predictor of fetal growth restriction.J Matern Fetal Neonatal Med.2022;35:9834-9836.

10. Farretti D, Vasapolo B, Pornstii F, et al. Maternal hemodynamics for the identification of early growth restriction in normotensive pregnancies.2022;129:12-14.Placenta.2022;129:12-12.

10. Vasaprolo B, Novelli GP, Gagliard G, Farsetti D, Valensise H. Pregnancy complications in chronic hypertensive patients are linked to pre-pregnancy maternal cardiac function and structure. Am J Obstet Gynecol. 2020;223(425):e1-425.e13.

102. Less, C., Sampallia T, Heukar T, Hecher K. Diagnosis and management of fetal growth restriction: The INSUGUE and comparison with the SMFM guideline.Ultrasound Obstet Gynecol. 2021;57:884-887.

1033. Ce, Tor, Sampalia R, Stapalia T, et al. Clinical Opinion: the diagnosis and management of suspected peakia. Systallia and prediction: an evidence-based approach.

104. Pathak S, Lees C, Hackett G, Jessop F, Seibre NJ. Frequency and clinical significance of placental histological lesions in an unselected population at or near term. Vircbows Arch.2011;459:565-572.

50.15. Binder J, Monaghan T, Chilanagahian B, Carta S, Khalil A. De-novo abnormal ureprolocal circulation in third timer: pregnancy outcome and pathological implications. Ultrasound Obstet Gynecol. 2018;52:60-65.

16. Scott D: PastapfanouI, Paraschi V, Clark K, Kametas NA. Longitudinal maternal hemodynamics in pregnancies that affected by fetal growth restriction. Ultrasound Obstet Gynecol. 2018;52:60-65.

17. Stampalija T, Wolf, Hylme-Raa, Bay et al. Reduced fetal growth velocity and weight loss are associated with diverse perinatal outcome in fetuses at risk of growth restriction. Am J Obstet Gynecol. 2023;228:71.e1-71.e10.

1087,PHEhman,Mantahou,Mantahou,E.Thilaganathan B,Khalil A.Are maternal hemodynamic indices markers of fetal growth restriction in pregnancies with a small-for-genteral-etaal F: Ultrasound Obstet Gynecol. 2023;228:71.e1-71.e10.

1091 Tamalia,Tfmanova,Tfmanah B,Aberi Mori M,et al. Late-term fetuses with reduced umbilical vein blood flow volume: an under-recognized population at increased risk of growth restriction. Ear J Obstet Gynecol Reprod Biol. 2022;272:182-187.

110. Hamidi O, Driver C, Steller JG, et al. Lumbil venous volume flow in late-onset fetal growth restriction. Ultrasound Med.2023;42:173-183.

111. Gorgione V, Ridder, Kalaft, E. Khalil A, Thilaganathan B. Incidence of postpartum hypertension with 2 years of a pregnancy complicated by pre-clampia: a systematic review and meta-analysis. BJOG.2021;128:495-503.

11. Honigberg MC, Zekavad M, Aragam K, et al. Long-term cardiovascu-lar risk in women with hypertension during pregnancy. J Am Coll Cardiol.2019;7473-2754.

13.McCarthy FP, Of Lollirad, Scetri, J., et al. Planned delivery to improve postpartum cardiac function in women with preterm pre-eclampsia: the PHOEBE mechanisms of action study within the PHOENIX RCT. Southampton(UK): NIHR Journals Library;2021; Sep.Efficacy and Mechanism Evaluation,No.8.12).

1415. Hicks Y.,Frans A, van Rijn BB, et al. Earlier age of onset of chronic hypertension and type 12 diabetes mellitus after a hypertensive disorder of pregnancy or gestational diabetes mellitus. Hypertension. 2015;66:1116-1122.

115. Boucher P, Laller G, Mouringes, O, E, et al. Hypertensive disorders of pregnancy and onset of chronic hypertension in France: the nationwide CONCEPTION study.Eur Heart J. 2022;43:3352-3361.

116. Stuart JJ,Tanz LJ,Misger S,A.,et al. Hypertensive disorders of pregnancy and maternal cardiovascular disease risk factor development. Ann Intern Med.Eur 18;2019;624.

17. Sharma S, Skog J, Timpea S, Impa E. Creeplampsia and high blood pressure in early pregnancy as risk factors of severe maternal cardiovascular disease during 50 years of follow-up. Pregnancy

18. Anne Cathrine Statoff,Redman C.Wang,Williams D,et al. Pregnancy and long-term material cardiovascular health progress through harmonization of research and cohorts. Biobynamics and Blommer. 2016;67:251-260.

11.Giorgione V, Khalil A,O',Ellison J, Thilaganathan B. Peripartum screening for postparamian hypertension in women with hypertensive disorders of pregnancy. J Am Coll Cardiol. 2022;80:1456-1476.

12020 Markov Ar, Stoust Jr, Horn et al. Does pregnancy complication history improve cardiovascular disease risk prediction? Findings from the HUNT study in Norway, Early Heart, JF 2019; H2011:1113-1120.

121. Schobler L, Schalekamp-Timmermans S, Brore-Brown ZA,et al. Placental growth factor as an indicator of maternal cardiovascular risk after pregnancy. Circulation.

122. Dal'As A, D'Antonio, F, Socome G, et al. Cardiovascular events following pregnancy complicate by pre-celampsia with emphasis on comparison between early- and late-ormt forms: systematic review and meta-analysis. Ultrasound Obstet Gynecol. 2021;57:698-709.

123. Castleman JS, Ganapathy R,Tak,F et al.Echocardiographic structure and function in hypertensive disorders of pregnancy: a systematic review. Circ Cardiovasc Imaging.2016;96:9704888.

1244 Red, Wright R., Holikrol, DnL, et al. Evaluation of cardiac function in women with history of precampiaia: a systematic review and meta-analysis. J Am Heart Imaging. 2009;2015;67:03454.

16

$$\text{ Consensus Statement}$$

125. Boksagl, Afranssen, McAl JA, Klm J, et al. Early-onsetepal maxpirates predisposes to preclinical stress: left ventricular dysfunction in the fifth decade of life: an observational study. PLoS One.2018;13:e0198809.

12. Countouris ME, Villanueva FS, Berlacher KL, et al. Association of hypertensive disorders of pregnancy with left ventricular remodeling in later life. J Am Coll Biol.2021;77:1057-1068.

12.74. Haug EB, Horn J, Markovitz AR, et al. Life course trajectories of cardiovascular risk factors in women with and without hypertensive disorders in first pregnancy-the hunt study. Nor 1. Am Heart Assoc. 2018;7(15):e00250.

128. Hoppe KK, Thomas N, Zernick M, et al. Telehealth with remote blood pressure monitoring with standard care for postpumum hypertension. Gynecol. 2020;223:583-588.

Kucker TL, Kerrh JP, Stevens JP, Rensultin- M. blood pressure in hypertension: a systematic review and individual data meta-analysis. PLoS Med. 2017;14:100239.

1302. Magee,Sadideh S. Prevention and treatment of postumptor hypertension.Cochrane Database Syst Rev. 2005(1):CD004351. doi:10.1002/14651858.CDD04315. pab2

113. Ayala, De Herida R, Mojén A, Ferminder, J Iglesia M. Circadian blood pressure variability in healthy and complicated pregnancies. Hypertension.1979;30:603-610.

12. Cairns AE, Tucker KL, Lissone P, Laenis A, Fermain R, Igleska A. Circadian the SNAP-HT HT. Hypertension. 2018;72:425-432.

133. Kitt A, Fox R, Cairns AE, et al. Short-term postpartum blood pressure self-management and long-term blood pressure control: a randomized controlled trial. Hypertension. 2018;77:425-432.

14. Lopes Perdigao J, Lewey J, Hirshberg A, et al. Furoseem for accelerated recovery of blood pressure postpartum in women with a hypertensive disorder of pregnancy: a randomized controlled trial. Hypertension 2021;78:469-479.

15. Anrter DK, Krah A, Blumenthal RS, 2019 ACC/AHA Guideline on the primary prevention of cardiovascular disease: past life, lifestyle and behavioral factors. JAMA Cardiol.2019;41034.

16. Orhermus I, Hongley S, Luckie M, et al. Postnatal enapril to improveavococyl-lar function following pretermopplcia(Epapl: postupl): a randomized double-blind-pacyloloo co-behavioral feasibility trial. Hypertension: 2020;76:18:18:187.

137 Algaes G. Algeo-screening for pregnancy complications by color Doppler assessment of the uterine arteries at 23'895' gestation. Obstet Gynecol.2000;96:539-564.

138. Schrolen, RR, Sepeters, L. Perne et al., Prereguey low-pluma volume and predisposition to preclampsia and fetal growth restriction. Obstet Gynecol.2011;117:1085-1093.

139. Schroen R, Longterting, FK Hopman, MTR and L. Low. Plasma volume in normative formerly preclamptic women predisposes to hypertension.Hypension 2015;66:1066-1072.

140.Schoren RR,Thishon DJR, Lotrigor F, Hopman MT, SpanderianMEA. Many Cardiovascular effects of aerobic exercise training in herforepen pre-ticric pain women and healthy porous carotri subjects. Am J Obstet Gynecol.Nary 2014;21:516-516.61.

11 Davenport MH, Sun R.M., Potrasi V, Pernoira V, Pernoira for the prevention gestational diabetes mellitus by Aftent. J Am Jest of systematic and methyl as- and Hypersse 2018;2:1367-1375.

142. Roln DL, Wright P, Donc L, et al. Acupin versus plascoic in pregnancies at high risk for preemptic preclampsia. EN J Med 2017;377:613-623.

143. McLaughlin K, Snelgrove JW, Sienes LE, et al. Phenotype-directed management of hypertension in pregnancy.J Am Heart Assoc,2022;21:0236948.

144. Novelli GP, Vapasculo B, Valensise H. Hemodynamic prediction and stratification of hypervisous disorders of pregnancy: a dream for that coming is that coming from a J Am Heart Assoc.2018;714(8100084.

15. Lees C, Ferrazzi E. Relevance of Hamodynamic dynamics in treating pre-clampia. Arran Hypertension Rep.2017;19:76.

14. Comente J, Buijs E, Revukot JJ, et J. Hemodynamic effects of intravenous nicpardine in severely pre-clomemine with a hypertensive crisis. Ultrasound Obstet Gynecol. 2016;47:89-95.

147. Corette J, Dveukot JJ, Roos-Hesselink JW, Hopc WJeC, Steergens EAP. Matal and fetal homodynamic effects of sulfidelipin in nonsmative frequentist women. JBOG.2011;18:5110-540.

148 Stott D, Stott D, Bolten M, et al. Longitudinal hemodynamics in acute phase of treatment with laborial in hypertensive pregnancy women to predict need for vasodilatory therapy. Ultrasound Obstet Gynecol. 2017;49:85-94.

149 Duan L, Ng, Chen W, Spencer HT, Lee M-S. Beta-blocker subtypes and risk of low birth with new iners. Jic Fluorescence 1003-2018;20:1603-1609.

150. Lansens and Dth M, Gyselaer W, PREMOM II: a multicenter. Randomized Pregancy Remote MOnoriting II study(PREMOM II): a multicenter, randomized controlled trial of remote monitoring for gestational hypertensive disorders. BMC Pregnancy Cldbirth, 2020:20:626.

151. Hypertension in Pregnancy. Diagnosis and Management. National Institute for Health and Care Excellence(NICE): 2019;2021

152. Tamas P, Hantosi E, Farkas B, et al. Preliminary study of the effects of ceremounide on blood pressure during late-onset pre-climpsia in patients with high cardiac output. Jtat Gynecol Obstet. JII 2016;18:73-89.

15. Evertral, Witt Isikin IB, Mahendra Hu, et al. A, Nirroglunathione improves haemodynamics in early-onset pre-clampsia. Br J Clin Pharmacol.2014;78:660-669.

154. Lang NN, Ahmad FA, Clilard Jg, JC et al. Hamodynamic effects of the nitrolyslor donor caminam(BMS-986231) in chronic heart failure: a randomized trial. Eur J Heart Fail.2021;231:1147-1155.

155. Kubo M, Umekawa T, Maekawa Y, et al. Retrospective study of tadafilaf for fetal growth restriction: Impact on maternal and perinatal outcomes. J Obstet Gynaecol Res.2017;43:291-297.

156 McLaughlin K, Hobson SR, Chandran AR, et al. Circulating maternal placental growth factor responses to low-molecular-weight heparin in pregnant patients at risk of placental dysfunction. Am J Obstet Gynecol. 2022;226;S1145-S1156.e1.

17.57. Trapani G.,Canvalles LF, Trapani TF, Artani TF, et al. Perinatal and hemodynamic evaluation of sulfidenal citrate for preclampsia treatment: a randomized controlled trial.Osterby Gcolyser.2016;228:235:29-19.

158. Pels A, Onalw R, Berger RM, Beiger et al. Neonatal pulmonary hypertension after severe early-onset fetal growth restriction: post hoc reflections on the Dutch STRIDER study.Ear J Pediatr,2022;181:1709-1718.

19. Pels A. Derk J.,Elv-Tasinpastar, A et al. Maternal sildenafil vs placebo in pregnant women with severe early-onset fetal growth restriction: a randomized clinical trial.AMKa Jene at Open. 2020;35:2032.

160. Ahmed A, Williams DJ, Dedek, V et al. Pravastatin for early-onset pre-eclampsia:a randomised,blinded, placebo-controlled trial. BJOG.2020;127:478-488.

16. Brownfoot FC, Tong, Hansan NJ, et al. Effects of pravastatin on human placentes, endolhenium, and women with severe preeclampsia. Hypertension.2015;66:687-697.

162.Paidas MJ,Tita ATNAMs GAG,et al. Prospective, randomized, double-blind,placbo-controlled evaluation of the pharmacokinetics, safety and efficacy of recombinant antihrombin versus placebo in preterm preclampsia. Am J Obstet Gynecol.2020;223:73e.u:173e.u.

16.Cruver CA,Hisocr R, Decade FH,et al. Use of metformin to prolong gestation in pre preclamp-enia: randomised, double blind, placebo controlled trial. BMJ.

16. De Rie A, Lees C, Martin M. Moncada S, Campbell S. Treatment of HELLP syndrome with nitric oxide donor. Lancet. 1995;345:124-125.

165. Le C. Langford E, Brown AS, et al. The effects of S-nitrosogulathione on platelet activation, hypertension, and uttine and fetal Doppler in severe preeclampsia.Olber Gynecol.1996;8:14:19.

166.Foo Fl. Mahendra Hu, Asini M., G, et al. Association between pregnancy cardiovascular function and subsequent preeclampsia or fetal growth restriction.Hypertension: 2018;74:424-425.

167. Vonr St, Selsalens, Asans Lens, and Development of a biophysical screening model for gestational hypertensive diseases. J Biomed Sci. 2019;26:38.

16.Ousan MW, Nath M, Khalil A, Haemodynamic differences amongst women who were created for diabetes in comparison to healthy controls.Pregnancy Hypertens.2018;14:23-28.

169.Osman MW, Nath M, Khalil A, et al. Haemodynamic differences amongst women haimodynamics in gravitational diabetes mellitus: a pilot study. Diabetes Res Clin Pract.2018;139:170-178.

171. Anness AR, Nath M, Osman MW, et al. Does treatment modality affect measures of arterial stiffness in women with gestational diabetes: Ultrasound Obstet Gynecol.

111. Anness AR, Clark A, Melhuish K, et al. Maternal hemodynamics and neonatal birth weight in pregnancies complications by gestational diabetes: new insights from novel causal inference analysis. Ultrasound Obstet Gynecol. 2022;60:215-222.

172. Mecacci F, Oantellano S, Vannelli S, Avanvilleini S, et al. Maternal hemodynamic changes in gestational diabetes: a prospective case-control study. Arcb Gynecol Obstet.

13.7 Masini G,Foo L, Fanley J, et al. Preeclampsia has two phenotypes which require different treatment strategies. Am J Obstet Gynecol. 2022;226:S1006-S1018.

17.5. Masupolo, B. Novelli GP, Valenisse H. Hemodynamic guided treatment of hypertensive disorders in pregnancy: is it time to change our mind? J Matern Fetal Neonatal Med.2021;34:3830-3831.

15. Valensis H, Fennasten D, Possen L, I et al. Friendly help for clinical use of maternal hemodynamics. J Matern Fetal Neonatal Med. 2021;34:3075-3079.

176.McLaughlin K, Scholten RR, Kingom JC, Floras JS, Parker JD. Should maternal hemodynamics guide antihypensive therapy in preeclampsia? Hypertension.

17. Report of the national high blood pressure education program working group on high blood pressure in pregnancy. Am J Obstet Gynecol. 2000;18:51-S22.

17. Brown CM, Garovic ND, Drug. Drug treatment of hypertension in pregnancy. Drugs.2014;27:234-89.

179. Massimani M, Tiralongo GM, Salivi S, et al. Treatment of pregnancies complicated by intrastratine growth restriction with nitric oxide donors increases placental expression of epidermal growth factor-like domain 7 and improves fetal growth: a pilot study. Trans Res 2011;28:228-41.

180. Vasapello, Bovelli GP,Gagliardi G, et al. Medical treatment of early-onset mild gravitational hypertension reduces total peripheral vascular resistance and influences maternal and fetal complications. Ultrasound Obstet Gynecol. 2012;40:325-331.

181. Valensise H, Vasapol B, Novelli GP, et al. Maternal and fetal hemodynamic effects induced by nitric oxide donors and plasma volume expansion in pregnancies with gestational hypertension complicated by intrauterine growth restriction with absent di-asclodic flow in the umbilical artery. Ultrasound Obstet Gynecol.2009;21:35:64.

18.Thakkar A, Hailu T. Bulimenthal R. RSs, et al. Cardio-obstetrics: the next frontier in cardiovascular disease prevention. Curr Atherosclerop Rep. 2022;24:493-507.

183. Dubberg BS, Sharma, R O'Driscoll JM, et al. Cardiac maladaptation in obese pregnant women at term. Ultrasound Obstet Gynecol. 2019;54:344-349.

184 Koenen M, Hill MA, Cohen P, Powers JR. Obesity, adipose tissue and vascular dysfior. Circ Res.2021:128:951-968.

185. Golinsky-Kgrayula K, Wichme: M, Golinski B, et al. Subclinical cardiac performance in obese and over weight women as a potential risk factor of preeplace. Pregnancy. Hypertension 2021;23:131-135.